Halozyme Therapeutics, Inc.

Revenue is increasingly recurring and diversified. Royalty revenue grew 52% year over year in the first half of 2025; Q2 2025 royalties increased 65% year over year.

Recent approvals for Tecentriq Hybreza, Ocrevus Zunovo, Opdivo Qvantig, and EU RYBREVANT SC expand the base, while additional partnered programs continue through late‑stage development. Patient and clinic time‑savings preferences support adoption of subcutaneous options, improving long‑term visibility.